Recombinant Human Lutropin alfa – CRI Report https://www.cri-report.com market research vender! Mon, 22 Nov 2021 06:14:56 +0000 en-US hourly 1 https://www.cri-report.com/wp-content/uploads/2021/01/cropped-shcrilogo-c.jpg Recombinant Human Lutropin alfa – CRI Report https://www.cri-report.com 32 32 Investigation Report on China’s Recombinant Human Follitropin Market, 2018-2022 https://www.cri-report.com/chinas-recombinant-human-follitropin-market/ Wed, 02 Jan 2019 02:40:11 +0000 https://www.cri-report.com/product/import-placeholder-for-1901371/ By the end of 2018, all the Recombinant Human Follitropin products in China were produced by Merck Serono and GeneScience Pharmaceuticals Co., Ltd. The sales value of Recombinant Human Follitropin kept rising after the drug was launched in China, reaching about CNY 548 million in 2017.

The post Investigation Report on China’s Recombinant Human Follitropin Market, 2018-2022 first appeared on CRI Report.

]]> Recombinant Human Follitropin Market Overview

According to CRI, as environmental pollution intensifies and Chinese people’s lifestyle changes, the incidence of infertility is increasing in China. In 2017, the incidence of infertility among married couples in China was 10%, more than double the 4.8% in 1984. It is estimated that about 15% to 20% women of childbearing age in China are troubled by infertility.

In China, as the biggest cause of female infertility, follicular dysplasia syndrome resulting from endocrine dysfunction accounts for over 40% of female infertility.

In China’s end markets of ART and sex hormone drugs, macromolecular bioengineered drugs such as Recombinant Human Follitropin, Recombinant Follitropin beta, Recombinant Human Chorionic Gonadotropin, and Recombinant Human Lutropin alfa are taking the place of small-molecule chemicals.

Follicle-stimulating hormone (FSH) is a heterodimeric glycoprotein formed by the non-covalent binding of subunits alpha and beta. FSH, luteinizing hormone (LH), thyroid-stimulating hormone (TSH) and human chorionic gonadotropin (HCG) are collectively known as the glycoprotein hormones family.

They share the same alpha subunit but differ from each other in beta subunit which determines their biological activity. FSH has important medicinal value in reproductive health. It can promote ovulation for natural production or artificial insemination, and can also help produce ova for in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI).

According to CRI, the FSH products in China include Urofollitropin (u-FSH) extracted from urine and Recombinant Human Follitropin (rh-FSH). Due to high purity and stability, Recombinant Human Follitropin (rh-FSH) has great advantages on the market.

In China, Recombinant Human Follitropin has been approved (1) to treat anovulation (including polycystic ovary syndrome, PCOS) that cannot be cured by Clomiphene Citrate; and (2) to be used for superovulation and follicular development by assisted reproductive treatment such as in vitro fertilization-embryo transfer (IVF-ET), gamete intrafallopian transfer (GIFT), and intracytoplasmic sperm injection (ICSI).

Merck Serono’s Recombinant Human Follitropin (trade name: GONAL-f) was approved to be marketed in China in 2008, and GeneScience Pharmaceuticals Co., Ltd.’s Jinsaiheng was also approved in 2015.

By the end of 2018, all the Recombinant Human Follitropin products in China were produced by Merck Serono and GeneScience Pharmaceuticals Co., Ltd. The sales value of Recombinant Human Follitropin kept rising after the drug was launched in China, reaching about CNY 548 million in 2017.

It is expected that the incidence of infertility will continue to grow as environmental pollution intensifies and Chinese people’s lifestyle changes. Meanwhile, as the average childbearing age of Chinese women continues to rise and China’s family planning policy is loosened, many older women plan to have a second child, which will drive the demand for Recombinant Human Follitropin in China.

In the coming years, more companies’ generic Recombinant Human Follitropin will be launched in China.

Topics Covered:
– Situation of infertility in China
– Status of China’s Recombinant Human Follitropin market
– Competition on China’s Recombinant Human Follitropin market
– Prices of Recombinant Human Follitropin in China
– Factors influencing the development of China’s Recombinant Human Follitropin market
– Prospect of China’s Recombinant Human Follitropin market from 2018 to 2022
– Progress of Recombinant Human Follitropin in China

Investigation Report on China’s Recombinant Human Thrombopoietin (rhTPO) Market 2021-2025

The post Investigation Report on China’s Recombinant Human Follitropin Market, 2018-2022 first appeared on CRI Report.

]]> Investigation Report on China’s Recombinant Human Lutropin alfa Market, 2018-2022 https://www.cri-report.com/investigation-report-on-chinas-recombinant-human-lutropin-alfa-market-2018-2022/ Thu, 13 Dec 2018 02:22:26 +0000 https://www.cri-report.com/product/import-placeholder-for-1812362/ Description According to the WHO’s estimate, infertility affects 15% to 20% of the global population. Survey data shows that in 2017, the incidence of infertility among married couples in China was 10%, more than double the 4.8% in 1984. As environmental pollution intensifies and the lifestyle changes, the incidence of infertility is increasing and infertility is increasingly prevalent among Chinese young people. About 15% to 20% women of childbearing age in China are troubled by infertility. As the biggest cause of female infertility in China, follicular dysplasia syndrome resulting from…

The post Investigation Report on China’s Recombinant Human Lutropin alfa Market, 2018-2022 first appeared on CRI Report.

]]> Description
According to the WHO’s estimate, infertility affects 15% to 20% of the global population. Survey data shows that in 2017, the incidence of infertility among married couples in China was 10%, more than double the 4.8% in 1984. As environmental pollution intensifies and the lifestyle changes, the incidence of infertility is increasing and infertility is increasingly prevalent among Chinese young people. About 15% to 20% women of childbearing age in China are troubled by infertility. As the biggest cause of female infertility in China, follicular dysplasia syndrome resulting from endocrine dysfunction accounts for over 40% of infertility cases. In addition to reasonable adjustments to menstrual period and etiological treatment, for fertilization, it is necessary to adopt an ideal solution to promote the development and maturation of follicles in clinical treatment.
Since 2015 when the Chinese government relaxed its family planning policy, sex hormone drugs have been growing rapidly, and the infertility treatment and IVF, an assisted reproductive technology (ART), have attracted much attention. In China’s end markets of ART and sex hormone drugs, macromolecular bioengineered drugs such as Recombinant Human Follitropin, Recombinant Follitropin Beta, Recombinant Human Chorionic Gonadotropin, and Human Lutropin alfa are taking the place of small-molecule chemicals.
Recombinant Human Lutropin alfa is a glycoprotein obtained by genetic engineering technique. It can combine with the luteinizing hormone/chorionic gonadotropin (LH/CG) receptor on the ovariole sheath (and granular layer) and the Leydig cell membrane. For women who lack luteinizing hormone and follicle-stimulating hormone (FSH) to ovulate, the use of LH can increase the level of estradiol secreted by the follicle and stimulate follicular development.
Merck Serono’s Recombinant Human Lutropin alfa (trade name: Luveris) was approved to be sold in China in 2008. In 2017, the sales value exceeded CNY 30 million. By the end of 2018, China’s Recombinant Human Lutropin alfa market is monopolized by Merck Serono. According to CRI’s analysis, multinational companies such as Merck Serono and Merck Sharp & Dohme dominate China’s fertility drug market. Meanwhile, Chinese companies such as Livzon Pharmaceutical Group Inc., GeneScience Pharmaceuticals Co., Ltd., Zhejiang Xianju Pharmaceutical Co., Ltd., Hybio Pharmaceutical Co., Ltd., and Chia Tai Tianqing Pharmaceutical Group Co., Ltd. are also launching generic drugs. It is expected that the pattern of China’s Recombinant Human Lutropin alfa market will change in the next few years.
In 2015, the Chinese government relaxed its “family planning policy” that had been implemented for over three decades, allowing each couple to have two children. In China, about 90 million women of childbearing age are eligible to have a second child. And an estimated 30% of them have the desire. Therefore, China’s fertility drug market is promising.

Topics Covered:
– Situation of infertility in China
– Overview of China’s fertility drug market
– Analysis on the fertility drug manufacturers in China
– Major factors influencing the development of fertility drugs in China
– Forecast on China’s Recombinant Human Lutropin alfa market from 2018 to 2022

The post Investigation Report on China’s Recombinant Human Lutropin alfa Market, 2018-2022 first appeared on CRI Report.

]]>